All In MedTech

Device Trial Radar · NCT07399496

Accelerated rTMS for Apathy in Parkinson's Disease

Last checked: Nov 19, 2026Latest source record: Nov 5, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Recruiting

Status

Recruiting

Enrollment

30

Planned (sponsor's estimate)

Start

Sep 9, 2026

Primary completion

Sep 9, 2027

Study completion Sep 9, 2027

Sponsor

Lead sponsor
Medical University of South CarolinaAcademic, hospital or other
Sponsor type
Academic, hospital or other
First posted
Feb 10, 2026

More device trials from this sponsor

Design

Study type
Interventional
Phase
Not applicable (typical for device studies)
Allocation
Not applicable (single group)
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated device
Yes
Who can join
All sexes, from 45 years, up to 85 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This single-site, open-label pilot study will evaluate the feasibility, tolerability, and preliminary efficacy of accelerated intermittent theta-burst stimulation (iTBS) targeting the dorsomedial prefrontal cortex (dmPFC) for apathy in individuals with Parkinson's Disease (PD). Fifteen participants with PD and clinically significant apathy will undergo imaging (EEG and MRI) and one day of TMS including twelve iTBS sessions across two visits. Outcomes include adherence, tolerability, changes in apathy (Lille Apathy Rating Scale), functional engagement, and neural target engagement assessed via resting-state fMRI and EEG. Follow-up assessments will occur at one week, two weeks, and four weeks post-treatment. Fifteen participants with PD without clinically significant apathy will act as a comparison group and will undergo imaging (EEG and MRI), assessments, and questionnaires at baseline. Caregivers for each participant will complete questionnaires regarding their co-participant's symptoms as well as answer questions about their experience as a caregiver.

Conditions

  • Parkinson Disease
  • Apathy

Interventions

  • Accelerated intermittent theta-burst stimulation (iTBS) rTMS to left dorsomedial prefrontal cortex (dmPFC)Device

    Accelerated intermittent theta-burst stimulation (iTBS) rTMS to left dorsomedial prefrontal cortex (dmPFC) (MagVenture MagPro with cooled figure-of-eight coil; Brainsight neuronavigation; 120% rMT; 1 treatment day; 12 sessions; 600 pulses/session; 10-15 min inter-session interval).

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. TMS adherenceTime frame: Day 1 through Day 14 (6 treatment days over approximately 2 weeks)
  2. Frequency and Severity of TMS-Induced Side effects (TMS tolerability and acceptability)Time frame: Measured during each treatment day (6 days within a 2-week period)
  3. Apathy severity as measured by the Lille Apathy Rating ScaleTime frame: Baseline (Day 0), immediately post-treatment (Day 14), 2 weeks post-treatment, and 4 weeks post-treatment

1 more outcomes with a free account

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Medical University of South Carolina

    Charleston, South Carolina · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.